Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease

Yaron Razon, Eldad Erez, Bernardo Vidne, Einat Birk, Jacob Katz, Hanna Tamari, Ovadia Dagan

Research output: Contribution to journalArticlepeer-review


Background: Postoperative bleeding and blood product requirements can be substantial in children undergoing open-heart surgery, and reexploration is required in 1% of cases. Recombinant activated factor VII (rFVIIa, NovoSeven®, NovoNordisk, Denmark) is a hemostatic agent approved for the treatment of hemophilic patients with inhibitors to factor VIII or factor IX. It has also been used with success in other conditions. We present our experience with rFVIIa treatment for uncontrolled bleeding after open-heart surgery in five pediatric patients. Methods: The study group consisted of five patients after open-heart surgery with excessive blood loss. The patients were treated with rFVIIa after failure of conventional treatment to control the bleeding. Blood loss, blood product consumption, and coagulation test results were recorded before and after rFVIIa administration. Results: In all cases, blood loss decreased considerably after rFVIIa administration (mean 7.8 ml·kg -1·h-1), almost eliminating the need for additional blood products, and the prolonged prothrombin time normalized. In two patients with thrombocytopathy, rFVIIa helped to discriminate surgical bleeding from bleeding caused by a defect in hemostasis. No side effects of rFVIIa treatment were noted. Conclusions: These cases support the impression that RFVIIa is efficient and safe in correcting hemostasis in children after cardiopulmonary bypass when other means fail. However, the data are still limited, and more extensive research is needed.

Original languageEnglish
Pages (from-to)235-240
Number of pages6
JournalPaediatric Anaesthesia
Issue number3
StatePublished - 2005


  • Cardiopulmonary bypass
  • Congenital heart disease
  • Postoperative bleeding
  • Recombinant factor VIIa


Dive into the research topics of 'Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease'. Together they form a unique fingerprint.

Cite this